Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you start immunotherapy in a patient with metastatic melanoma who is on steroids (e.g. dexamethasone for cerebral edema)?
Or would you try to wait and get the steroids off first?
Answer from: Medical Oncologist at Academic Institution
In general immunotherapy should not be started if patients require predisone or the equivalent more than 10 mg a day.
Sign In
or
Register
to read more
2357
Related Questions
How, if at all, are you modifying your practice and clinical workflow for patients receiving checkpoint inhibitors with data showing improved outcomes for patients receiving infusions earlier in the day?
Would you consider neoadjuvant immunotherapy prior to radiation for a locally advanced skin squamous cell carcinoma?
What is the optimal approach to managing oral toxicities, such as dysgeusia, caused by immune checkpoint inhibitors (ICIs)?
How would you manage a patient who developed stage III melanoma while receiving cemiplimab (cycle 10) for locally advanced cutaneous squamous cell carcinoma?
How should medical oncologists and dermatologists communicate about patients with at least Stage IIB/III cutaneous melanoma regarding neoadjuvant immunotherapy?
When would you offer neoadjuvant immunotherapy prior to Mohs surgery in a locally advanced squamous cell carcinoma for which clearance may require enucleation?
If adjuvant radiation is offered to an elderly patient with H&N SCC s/p Mohs surgery who is planned for multi-stage reconstruction of the defect with plastic surgery, when should adjuvant radiation be started?
In what situations would you recommend adjuvant radiation therapy for patients with locally advanced and/or recurrent basal cell carcinoma that receive vismodegib followed by surgery?
How have you used Hedgehog pathway inhibitors as neoadjuvant/adjuvant therapies?
How would you approach management of a large, fungating squamous cell carcinoma of the auricle if surgical management is not desired by the patient?